LEXINGTON, Mass. , July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024 .
LEXINGTON, Mass. , July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Eric Hall , Ph.D., M.B.A. that, among other things, provides for the grant to Dr.
LEXINGTON, Mass. , July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Nathan Jorgensen , Ph.D., M.B.A. that, among other things, provides for the grant to
LEXINGTON, Mass. , June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024
LEXINGTON, Mass. , June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen , Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024 .
LEXINGTON, Mass. , May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an
- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - - Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and efficacy demonstrated in Alzheimer’s disease and ALS gene therapies; low IV doses provided broad CNS
LEXINGTON, Mass. , May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024 .
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALS LEXINGTON, Mass. , April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc.
